The HIV epidemic caused a considerable rise in the incidence of oral candidiasis. The infection may spread down into the esophagus when the CD4+ cell count falls below 100/μL. This patient’s advanced disease made him vulnerable to the dramatic spread. Topical treatment for oral candidiasis is not as effective when there is esophageal involvement.
A 38-year-old man had fever and fatigue for the past 6 days and tenderness in the left upper abdominal quadrant for the past 3 days. He also had a facial butterfly rash that had been present for 10 years and a 1-year history of lupus nephritis, treated with prednisone and mycophenolate. He denied respiratory complaints or recent weight loss.
Social media and mobile-based apps have the potential to reach many more people with HIV-prevention and treatment messages; but, are these approaches are effective? Read More
More than 1300 physicians of all specialties responded to the 2012 survey. Many of the respondents are primary care physicians. See how your colleagues responded and learn what concerns them most.Read more
Infectious disease expert Rodger MacArthur, MD, offers insights and points readers to updated comprehensive guidelines on managing side effects.Read More
Chlamydia trachomatis, serovar L2b——a recently discovered microbe——was the cause of atypical lymphogranuloma venereum in this HIV-positive patient. More »
A closer look at racial disparities in treatments for rheumatoid arthritis and osteoarthritis show nuanced explanations for why African Americans are less willing to undergo drug therapy and surgery. More careful and clearer communication may go a long way toward closing the gap. More »
Finding a plethora of federal recommendations on managing illicit drug-use behaviors and sexually transmitted infections including HIV, the Centers for Disease Control and Prevention has weighed in on organized management of these health issues that often coincide. More »
Are some of your HIV-positive patients non-adherent to their ART therapy? Consider a carefully planned conversation about their drinking habits. More »
Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH. More »
(AUDIO) US Preventive Services Task Force recommendations for HIV screening may come into line with CDC guidelines thanks to a reanalysis of recent outcomes data. Here clinical epidemiologist Roger Chou MD, who conducted the analysis, describes the new evidence and the implications. More »
The number of medical diseases that can present with psychotic symptoms (ie, delusions, hallucinations) is legion. A thorough differential diagnosis of possible medical and toxic causes of psychosis is necessary to avoid the mistaken attribution of psychosis to a psychiatric disorder. More »
A recently published study highlights a growing problem in HIV/AIDS patients: A substantial proportion are now overweight or obese, mirroring the US population at large. More »
Data from an inner-city AIDS treatment clinic in Baltimore suggest that inequities in HIV/AIDS treatment may be undergoing a necessary correction. In this podcast, an author of the study explains what this may mean for people in treatment elsewhere. More »
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of human immunodeficiency virus (HIV)-positive pregnant women in the UK. The scope includes guidance on the use of antiretroviral therapy (ART) both to prevent HIV mother-to-child transmission (MTCT) and for the welfare of the mother herself, guidance on mode of delivery and recommendations in specific patient populations where other factors need to be taken into consideration,such as coinfection with other agents. The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of pregnant women with HIV infection.
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection with antiretroviral therapy (ART). The scope includes: (i) guidance on the initiation of ART in those previously nave to therapy; (ii)support of patients on treatment; (iii) management of patients experiencing virological failure; and (iv) recommendations in specific patient populations where other factors need to be taken into consideration. The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.
The aim of this study was to estimate the relative risk of cardiovascular disease (CVD) among people living with HIV (PLHIV) compared with the HIV-uninfected population.|We conducted a systematic review and meta-analysis of studies from the peer-reviewed literature. We searched the Medline database for relevant journal articles published before August 2010. Eligible studies were observational and randomized controlled trials, reporting CVD, defined as myocardial infarction (MI), ischaemic heart disease, cardiovascular and cerebrovascular events or coronary heart disease among HIV-positive adults. Pooled relative risks were calculated for various groupings, including different classes of antiretroviral therapy (ART).|The relative risk of CVD was 1.61 [95% confidence interval (CI) 1.43-1.81] among PLHIV without ART compared with HIV-uninfected people. The relative risk of CVD was 2.00 (95% CI 1.70-2.37) among PLHIV on ART compared with HIV-uninfected people and 1.52 (95% CI 1.35-1.70)
22900734 2012 08 20 2012 10 18 1751-486X 16 1 2012 Feb-Mar Nurs Womens Health 88-9 10.1111/j.1751-486X.2012.01711.x Association of Women s Health, Obstetric &Neonatal Nursing eng Journal Article Practice Guideline United States Nurs Womens Health
Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7-3.9 million persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical monitoring) and treatment. CDC estimates that although persons born during 1945-1965 comprise an estimated 27% of the population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associated mortality, and are at greatest risk for hepatocellular carcinoma and other HCV-related liver disease. With the advent of new therapies that can halt disease progression and provide a virologic cure (i.e., sustained viral clearance following completion of treatment) in most persons, targeted testing and linkage to care for infected persons in this birth cohort is expected to reduce HCV-related morbidity and mortality. CDC is augmenting previous recommendations for HCV testing (CDC. Recommendations
The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of
23403670 2013 02 13 2013 02 19 1538-3598 309 6 Feb 13 JAMA 545-6 10.1001/jama.2012.216991 Padayatty Sebastian J SJ Levine Mark M eng Comment Letter United States JAMA 7501160 0098-7484 0 Vitamins 12001-76-2 Vitamin B Complex 1406-18-4 Vitamin E 50-81
23403671 2013 02 13 2013 02 19 1538-3598 309 6 Feb 13 JAMA 546 10.1001/jama.2012.216995 Isanaka Sheila S Mugusi Ferdinand F Fawzi Wafaie W WW eng Comment Letter United States JAMA 7501160 0098-7484 0 Vitamins 12001-76-2 Vitamin B Complex 1406-18-4
Huge increases in funding for international health over the past two decades have led to a proliferation of donors, partnerships, and health organisations. Over the same period, the global burden of non-communicable diseases has increased absolutely and relative to communicable diseases. In this changing landscape, national programmes for the control of HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases must be reinforced and adapted for three reasons: the global burden of these communicable diseases remains enormous, disease control programmes have an integral and supporting role in developing health systems, and the health benefits of these control programmes go beyond the containment of specific infections. WHO's traditional role in promoting communicable disease control programmes must also adapt to new circumstances. Among a multiplicity of actors, WHO's task is to enhance its normative role as convenor, coordinator, monitor, and standard-setter, fostering greater
The expression of endogenous retroviruses of the HERV-K(HML-2) family is strongly upregulated in germ cell tumors and several other cancers. Although the accessory Rec protein of HERV-K(HML-2) has been shown to induce carcinoma in situ in transgenic mice, to increase the activity of c-myc and to interact with the androgen receptor (AR), whether or not Rec expression is indeed implicated causally in the initiation or progression of any human malignancies remains unclear. We used the yeast two-hybrid system involving the Rec protein of a recently integrated HERV-K(HML-2) element in an effort to identify potential Rec-related oncogenic mechanisms. This revealed the human small glutamine-rich tetratricopeptide repeat (TPR)-containing protein (hSGT) to be a cellular binding partner. The interaction of Rec with this known negative regulator of the AR was confirmed by coimmunoprecipitation, pull-down assays and colocalization studies. The interaction involves the TPR motif of hSGT and takes
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
The HIV epidemic caused a considerable rise in the incidence of oral candidiasis. The infection may spread down into the esophagus when the CD4+ cell count falls below 100/μL. This patient’s advanced disease made him vulnerable to the dramatic spread. Topical treatment for oral candidiasis is not as effective when there is esophageal involvement.
A 38-year-old man had fever and fatigue for the past 6 days and tenderness in the left upper abdominal quadrant for the past 3 days. He also had a facial butterfly rash that had been present for 10 years and a 1-year history of lupus nephritis, treated with prednisone and mycophenolate. He denied respiratory complaints or recent weight loss.
